Orkambi Tablet, Film Coated
NDC Package 51167-809-01
Package Information
Orkambi (lumacaftor and ivacaftor) tablets is a medication a combination of 2 medications: lumacaftor and ivacaftor. This formulation utilizes a tablet, film coated delivery system. Marketed by Vertex Pharmaceuticals Incorporated, this product is identified by NDC 51167-809 and is authorized under FDA application NDA206038.
Identification & Billing
- RxCUI: 1655928 - lumacaftor 200 MG / ivacaftor 125 MG Oral Tablet
- RxCUI: 1655928 - ivacaftor 125 MG / lumacaftor 200 MG Oral Tablet
- RxCUI: 1655934 - ORKAMBI 200 MG / 125 MG Oral Tablet
- RxCUI: 1655934 - ivacaftor 125 MG / lumacaftor 200 MG Oral Tablet [ORKAMBI]
- RxCUI: 1655934 - ORKAMBI (lumacaftor 200 MG / ivacaftor 125 MG) Oral Tablet
Clinical Specifications
- Chloride Channel Activation Potentiators - [MoA] (Mechanism of Action)
- Cystic Fibrosis Transmembrane Conductance Regulator Potentiator - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 2B6 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C19 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C8 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C8 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 2C9 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C9 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inducers - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 51167 - Vertex Pharmaceuticals Incorporated
- 51167-809 - Orkambi
- 51167-809-01 - 4 CARTON in 1 BOX / 7 BLISTER PACK in 1 CARTON / 4 TABLET, FILM COATED in 1 BLISTER PACK
- 51167-809 - Orkambi
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51167-809-01 identifies a specific commercial package of 4 carton in 1 box / 7 blister pack in 1 carton / 4 tablet, film coated in 1 blister pack of Orkambi, a human prescription drug labeled by Vertex Pharmaceuticals Incorporated. This product is billed for "EA" each discreet unit and contains an estimated amount of 4 billable units per package. This tablet, film coated is formulated for oral use and contains ivacaftor; lumacaftor as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vertex Pharmaceuticals Incorporated on July 02, 2015. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is a combination of 2 medications: lumacaftor and ivacaftor. It is used to treat cystic fibrosis in certain people (those with 2 copies of an abnormal "CFTR" gene). It may help to improve breathing, reduce the risk of lung infections, and improve weight gain.
How is this Vertex Pharmaceuticals Incorporated product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51167080901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.